Intelligent Bio Solutions Q4 FY2023 revenue up 355% to $1.99M; net loss widens to $10.6M

INTELLIGENT BIO SOLUTIONS INC.

2023-FY EPS reported -$10.58 vs consensus -$33.05 ▲ beat (+68.0%)

Combined revenue & govt support income $1.99M (+355% YoY); product sales $1.26M.
Net loss attributable to INBS $10.6M (vs $8.3M prior year); includes $4.2M goodwill impairment.
Cash and equivalents $1.5M at June 30, 2023.
Received FDA guidance for 510(k) pathway for its Intelligent Fingerprinting Drug Screening Cartridge.
Expanded into Australia; secured 8 new customers; awarded 13th patent.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. reported fiscal year ended June 30, 2023 results: revenue $1.99 million, net income $10.6 million loss.

Period: fiscal year ended June 30, 2023
Revenue: $1.99 million
Net income: $10.6 million loss
Result: reported results

Exact text from the filing

The Company’s combined revenue and government support income increased by 355% to $1.99 million for the fiscal year ended June 30, 2023, including revenue from sales of goods of $1.26 million, compared to fiscal year 2022.

View on SEC.gov

Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-030140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.